This week in therapeutics




Licensing status

Publication and contact information

Autoimmune disease


B and
T lymphocyte attenuator

Cell culture and mouse studies suggest agonizing BTLA could help treat psoriasis. In a subset of cultured gd T cells treated with Il-7, Btla knockout cells showed greater proinflammatory Il-17 and tumor necrosis factor (TNF) production than wild-type cells. In a mouse model of acute dermatitis, Btla knockout mice had more severe inflammation than wild-type mice. In wild-type mice with acute dermatitis, an antibody that agonizes Btla decreased epidermal thickening compared with no treatment. Next steps in collaboration with Pfizer Inc.'s Center for Therapeutic Innovation include targeting BTLA with its ligand, tumor necrosis factor receptor superfamily
member 14 (HVEM; TNFRSF14; LIGHTR).

SciBX 7(4); doi:10.1038/scibx.2014.109
Published online Jan. 30, 2014

Patent and licensing status undisclosed

Bekiaris, V. et al. Immunity; published online Dec. 5, 2013;
Contact: Carl F. Ware,
Sanford-Burnham Medical Research Institute, La Jolla, Calif.